ramucirumab,trastuzumab,paclitaxel
eli lilly
['ramucirumab', 'paclitaxel', 'trastuzumab,(-trastuzumab deruxtecan),(-trastuzumab-deruxtecan)']
trastuzumab + ramucirumab/paclitaxel in pretreated her2 + gc/gej cancers phs-ii, 50 pts interesting signal of efficacy for continuation of trastuzumab in 2nd line despite loss of her2 in 35% of cases (not predictive ?) 
Physician-scientist, focused on translational research in hepatobiliary cancer and precision oncology